DexCom, Inc. $DXCM Shares Newly Purchased by Kestra Investment Management LLC

Kestra Investment Management LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,467 shares of the medical device company’s stock, valued at approximately $1,594,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Latitude Advisors LLC acquired a new stake in shares of DexCom during the third quarter worth $32,000. Hilton Head Capital Partners LLC lifted its position in DexCom by 242.3% in the 3rd quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock valued at $33,000 after acquiring an additional 269 shares in the last quarter. Ascentis Independent Advisors bought a new stake in DexCom in the 1st quarter valued at $25,000. Elevation Wealth Partners LLC lifted its position in DexCom by 61.0% in the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after acquiring an additional 152 shares in the last quarter. Finally, GK Wealth Management LLC bought a new stake in DexCom in the 3rd quarter valued at $35,000. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 3,638 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the completion of the sale, the executive vice president owned 146,828 shares of the company’s stock, valued at $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the sale, the director owned 29,293 shares in the company, valued at $2,461,783.72. This represents a 18.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 22,822 shares of company stock valued at $1,920,193. 0.28% of the stock is owned by insiders.

DexCom Stock Performance

NASDAQ DXCM opened at $79.92 on Wednesday. The firm has a 50-day moving average of $84.79 and a 200-day moving average of $75.08. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74. The stock has a market cap of $29.81 billion, a PE ratio of 31.34, a P/E/G ratio of 1.34 and a beta of 1.45. DexCom, Inc. has a 52-week low of $55.84 and a 52-week high of $92.59.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.61 earnings per share. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DXCM shares. Robert W. Baird set a $105.00 price target on DexCom and gave the company an “outperform” rating in a research note on Friday, July 31st. Piper Sandler restated an “overweight” rating and issued a $95.00 price target (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Jefferies Financial Group upped their price objective on DexCom from $112.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a report on Sunday, September 6th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $97.00 price objective (up from $94.00) on shares of DexCom in a report on Friday, October 30th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $95.50.

About DexCom

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.